香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，幷明確表示概不就因本公告全部或任何部分內容而産生或因 依賴該等內容而引致之任何損失承擔任何責任。 ( 於中華人民共和國註冊成立的股份有限公司 ) (股份代號：1666) 續訂持續性關連交易 新商標許可協議 新商標許可協議 茲提述本公司日期為二零零零年十月二十四日之招股書及日期為二零零二年六月七日之 通函，其中內容有關本公司與集團公司訂立商標許可協議。董事會謹此宣佈，由於本公 司與集團公司訂立之現有商標許可協議將於二零二四年十二月三十一日到期，故訂約各 方於二零二四年十二月三十日（交易時段後）同意續訂該協議並訂立新商標許可協議， 以允许本集團使用「同仁堂」字號及部分商標，協議期限自二零二五年一月一日起至二 零二七年十二月三十一日止，並訂立上述協議項下截至二零二七年十二月三十一日止三 個年度之擬進行之持續關連交易年度上限。 香港上市規則的涵義 截至本公告日，集團公司為本公司之最終控股股東，故根據香港上市規則為本公司之關 連人士，新商標許可協議項下擬進行之交易構成香港上市規則第14A章下規定的本公司 之持續 ...

（股份代號：1666） 內幕消息 修訂企業年金方案實施細則 本公告乃由北京同仁堂科技發展股份有限公司（「本公司」，及其附屬公司統稱「本集團」） 根據證券及期貨條例第XIVA部（香港法例第571章）和香港聯合交易所有限公司證券上 市規則第13.09條作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） 茲提述本公司日期為二零二一年六月二十五日之公告（「公告」），內容有關本公司參加 中國北京同仁堂（集團）有限責任公司企業年金計劃並制定本公司企業年金方案實施細 則。除另有界定者外，本公告所用詞彙與該公告所界定者具有相同涵義。本公司已實施 企業年金計劃 （「企業年金方案」），並已制定本公司企業年金方案實施細則（「企 業年金方案實施細則」），自二零二一年七月一日起開始生效。企業年金的繳費基數以 員工上一年度月平均工資為基數，唯不得超過北京市上一年度月平均工資的五倍，其 中，員工繳費比例為2%，本公司繳費比例為6%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1666） 更改香港H股股份過戶登記處 北京同仁堂科技發展股份有限公司（「本公司」）之董事會（「董事會」）謹此宣佈， 自二零二四年十一月一日起，本公司之香港H股股份過戶登記處將更改為： 香港中央證券登記有限公司 香港 灣仔 皇后大道東183號 合和中心17樓 1712-1716號舖 電話號碼: (852) 2862 8555 傳真號碼: (852) 2865 0990 自二零二四年十一月一日起，本公司的股份過戶及登記手續申請此後應遞交至香港中央 證券登記有限公司（「 香港中央證券」） 辦理。於二零二四年十月三十一日下午四時 三十分後仍未領取之股票, 可於二零二四年十一月一日起從香港中央證券領取。 1 承董事會命 二零二四年十月二十九日 於本公告日期，董事會包括執行董事邸淑兵先生、陳加富先生及馮智梅女士；非執行董 事張毅先生、王春蕊女士及馮莉女士；獨 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性概不作任何陳述，並明確表示概不就因本公告的全部或任何部分內容而 產生或因依賴本公告的全部或任何部分內容而產生或因依賴本公告的全部或任何部分內 容而產生的任何損失承擔任何責任。 承董事會命 北京同仁堂科技發展股份有限公司 邸淑兵 董事長 中國，北京 二零二四年十月二十九日 （於中華人民共和國註冊成立的股份有限公司） 於本公告日期，董事會包括執行董事邸淑兵先生、陳加富先生及馮智梅女士；非執行董 事張毅先生、王春蕊女士及馮莉女士；獨立非執行董事陳清霞女士、詹原競先生及李兆 彬先生。 （股份代號：1666） 聯席公司秘書辭任 北京同仁堂科技發展股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，翁 美儀女士（「翁女士」）因工作調整，辭任本公司聯席公司秘書（「聯席公司秘書」） 職務，自二零二四年十月二十九日起生效。翁女士確認與董事會並無意見分歧，亦無任 何與其辭任有關的事宜需要提請本公司股東或香港聯合交易所有限公司（「香港聯交 所」）垂注。 翁女士辭任後，另一位聯席公司秘書李一俊先生，作為具備香港聯交所證券上市規則 第3.2 ...

有關二零二四年三季度財務信息之公告 北京同仁堂科技發展股份有限公司（「本公司」）根據《證券及期貨條例》（香港法例第 571章）第XIVA部及香港聯合交易所有限公司證券上市規則第13.09條作出本公告。 本公司控股股東北京同仁堂股份有限公司（「同仁堂股份」）將於二零二四年十月三十日 在上海證券交易所公佈其截至二零二四年九月三十日止九個月未經審計之三季度業績，該 業績包含本公司及其附屬公司（「本集團」）截至二零二四年九月三十日止九個月未經審 計的財務信息。為保證本公司全體股東公平、及時地知曉本公司信息，本公司特此公佈以 下財務信息：根據中華人民共和國財政部頒佈的《中華人民共和國企業會計準則》，截至 二零二四年九月三十日止九個月，本集團未經審計營業收入約人民幣548,436萬元，未經審 計營業成本約人民幣330,692萬元，未經審計歸屬於母公司所有者的淨利潤約人民幣54,641 萬元。於二零二四年九月三十日，本集團未經審計總資產約人民幣1,394,690萬元。 1 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部份內 ...

京同仁登 Tong Ren Tang Technologies Co. Ltd. 北京同仁堂科技發展股份有限公司 《射中華人民共和國駐田成立始設份有限公司] (股份代值:1666) NICE NO DO DES DESIDENT FOR DENNE 中期業績 9 45 1230 ▲ 0000 WHEN MAN NEW YORK BOOK BOOK analana and C C 4 bell 25 100 e | --- | --- | |-------|--------------------------------------------------------------------------------| | | | | 摘要 | | | · | 截至二零二四年六月三十日止六個月,本集團銷售收入較二零二三年同期上漲 約 2.63% • | | . | 截至二零二四年六月三十日止六個月,歸屬於本公司所有者之利潤較二零二三 | | | 年同期上漲約16.46%。 | | . | 截至二零二四年六月三十日止六個月,歸屬於本公司所有者之每股收益為人民 | | | 幣 0.33 元 · | | . | 董事會 ...

Financial Performance - For the six months ended June 30, 2024, the group's sales revenue increased by approximately 2.63% compared to the same period in 2023, reaching RMB 4,050,094,000[4] - The profit attributable to the owners of the company for the same period rose by approximately 16.46% year-on-year, amounting to RMB 428,752,000[4] - The earnings per share attributable to the owners of the company for the six months ended June 30, 2024, was RMB 0.33, compared to RMB 0.29 for the same period in 2023[4] - The total comprehensive income for the period was RMB 604,055,000, a decrease from RMB 664,847,000 in the previous year[7] - The company reported a net operating profit of RMB 632,045,000 for the period, a slight decrease from RMB 640,630,000 in the previous year[4] - The total revenue for the six months ended June 30, 2024, was RMB 4,050,094,000, compared to RMB 3,946,415,000 in the same period last year, reflecting a growth of 2.6%[22] - The company reported a profit of RMB 582,784,000 for the period, with the company's segment contributing RMB 302,703,000[39] Assets and Liabilities - The total assets as of June 30, 2024, amounted to RMB 14,288,922,000, an increase from RMB 13,507,742,000 as of December 31, 2023[10] - The company's non-current assets were valued at RMB 3,476,625,000, slightly up from RMB 3,448,844,000 at the end of 2023[9] - The total liabilities as of June 30, 2024, were RMB 4,442,717,000, compared to RMB 3,855,857,000 at the end of 2023[10] - The company's cash and cash equivalents increased to RMB 3,942,070,000 from RMB 2,746,458,000 at the end of 2023[9] - Accounts receivable and notes receivable totaled RMB 1,295,880,000 as of June 30, 2024, up from RMB 952,456,000 as of December 31, 2023, representing a growth of approximately 36%[32] - The total accounts payable decreased to RMB 973,406,000 as of June 30, 2024, from RMB 1,376,743,000 as of December 31, 2023, reflecting a reduction of approximately 29%[36] Cash Flow - For the six months ended June 30, 2024, the net cash flow from operating activities was RMB (452,882) thousand, a decrease from RMB 848,473 thousand in the same period of 2023[11] - The net cash flow from investing activities showed a significant increase to RMB 1,055,672 thousand in 2024, compared to a net outflow of RMB (376,022) thousand in 2023[12] - Cash flow from financing activities resulted in a net inflow of RMB 581,162 thousand in 2024, compared to a net outflow of RMB (208,695) thousand in 2023[12] - The total cash and cash equivalents at the end of June 30, 2024, amounted to RMB 3,942,070 thousand, slightly down from RMB 4,064,607 thousand at the end of June 30, 2023[12] Dividends - The company did not declare an interim dividend for the six months ended June 30, 2024[2] - The board of directors decided not to declare an interim dividend for the six months ending June 30, 2024, and proposed a cash dividend of RMB 0.18 per share for the year ending December 31, 2023, totaling RMB 230,541,000[30] - The company paid dividends of RMB (230,541) thousand to shareholders for the fiscal year 2023[13] Revenue by Segment - Traditional Chinese medicine product sales revenue in mainland China reached RMB 3,552,169,000, an increase of 7.3% from RMB 3,311,352,000 in the same period last year[22] - Advertising service revenue totaled RMB 4,019,560,000, up 2.6% from RMB 3,918,284,000 year-on-year[22] - Revenue from the company's segment in mainland China was RMB 2,766,628,000 for the six months ending June 30, 2024, while revenue from Tong Ren Tang Chinese Medicine was RMB 605,295,000[39] Tax and Expenses - The company incurred a current income tax expense of RMB 93,447,000, a decrease of 9.0% from RMB 103,442,000 in the previous year[27] - Depreciation of property, plant, and equipment amounted to RMB 90,758,000, an increase of 2.8% from RMB 88,505,000 year-on-year[25] - Research and development expenditure was RMB 2,751.0 million, accounting for 0.68% of revenue as of June 30, 2024, down from 1.21% in the previous year[75] Shareholder Information - Major shareholders include Tong Ren Tang Holdings, which holds 600,000,000 shares, representing 92.01% of domestic shares and 46.85% of total voting shares[90] - Hillhouse Capital holds 47,663,000 shares, representing 7.58% of H shares and 3.72% of total registered capital[91] - The group company owns 600,000,000 shares of Tongrentang, equating to a 52.45% equity interest as of June 30, 2024[91] Corporate Governance and Compliance - The company has adhered to the corporate governance code and has not identified any non-compliance during the reporting period[82] - The audit committee has reviewed the unaudited financial statements for the six months ending June 30, 2024, and found no objections to the accounting treatment[87] - The company will continue to strengthen risk management and internal control systems to minimize operational risks[84] Strategic Initiatives - The company aims to enhance product operating rates and market share through targeted marketing activities in the second half of the year[80] - The focus for production will be on maintaining production value, product variety, and supply chain efficiency to respond to market demands[80] - The marketing strategy will continue to emphasize the "big variety" strategy, enhancing competitiveness and market share[81] - The company is committed to deepening marketing reforms and focusing on core products to drive growth[81] Product Development - The company launched new products including the Qishen Granules, which received clinical trial approval, and expanded its product matrix with various new offerings[65] - The company focuses on developing four main product types: granules, water honey pills, tablets, and soft capsules[96] - The company has a commitment to prioritize the manufacturing and sales of new products developed by the group or its subsidiaries within its main product categories[96]

Financial Performance - The Group's revenue for the year ended December 31, 2023, was reported at RMB 1.2 billion, reflecting a year-on-year increase of 15%[17]. - Gross profit for the same period was RMB 800 million, resulting in a gross margin of 66.7%[17]. - Profit attributable to owners of the Company reached RMB 300 million, with an increase of 20% compared to the previous year[17]. - Earnings per share for 2023 were RMB 0.75, up from RMB 0.62 in 2022, indicating a growth of 20.9%[17]. - For the year ended December 31, 2023, the Group's revenue was RMB 6,773,463,000, an increase of 13.04% from RMB 5,991,841,000 in the previous year[22]. - The net profit for the year was RMB 992,313,000, a decrease of 0.93% from RMB 1,001,620,000 in the previous year[22]. - Profit attributable to owners of the Company was RMB 590,188,000, an increase of 1.25% from RMB 582,888,000 in the previous year[22]. - The gross margin for the year was 45.90%, and the net profit margin was 16.56%[22]. - The total income for 2023 was RMB 6,773,463,000, representing an increase from RMB 5,991,841,000 in 2022[85]. Liquidity and Financial Ratios - The current ratio improved to 2.5, while the quick ratio stood at 1.8, indicating strong liquidity[17]. - The debt to asset ratio was reported at 30%, reflecting a stable financial structure[17]. - Return on equity for the year was 12%, showing an increase from 10% in the previous year[17]. - Total assets amounted to RMB 10,469,970,000, with total liabilities of RMB 3,055,396,000, resulting in a debt to asset ratio of 29.18%[22]. - The Group's liquidity ratio was 4.9 as of December 31, 2023, compared to 4.42 in the previous year, indicating sufficient financial resources[55]. - The gearing ratio as of December 31, 2023, was 0.15, slightly down from 0.16 in the previous year, indicating a stable capital structure[56]. - The trade receivables turnover ratio improved to 7.97 from 6.79, reflecting stronger liquidity in trade receivables[55]. Market Expansion and Product Development - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in regional sales by 2025[17]. - New product lines in herbal supplements are expected to launch in Q2 2024, aiming to capture a larger market share[17]. - The Group aims to enhance its core competitive advantages and achieve high-quality development in line with the "14th Five-Year Plan"[27]. - The outlook for 2024 indicates continued government support for the traditional Chinese medicine industry and potential for global expansion[27]. - The Group plans to leverage its brand "Tong Ren Tang" to promote traditional Chinese medicine culture and improve marketing effectiveness[28]. - Key initiatives for 2024 include improving variety management, channel expansion, and marketing capabilities, focusing on "Major Varieties" and the "Glow Campaign"[79]. Subsidiary Performance - The sales revenue of Tong Ren Tang Chinese Medicine and its subsidiaries was RMB 1,376,532,000, representing a year-on-year decrease of 7.94%[41]. - The sales amount of Shengmai Liquor increased by 70.63%, while Ganmao Qingre Granules increased by 27.42% compared to the previous year[36]. - Tong Ren Tang WM achieved sales revenue of RMB 90,681,000, representing a year-on-year increase of 62.66%, and net profit of RMB 823,000, representing a year-on-year increase of 34.04%[42]. - Tong Ren Tang Guo Yao reported sales revenue of RMB 137,653,200, a year-on-year decrease of 7.94%, and net profit of RMB 48,694,800, a year-on-year decrease of 12.62%[44]. - The two subsidiaries, Tong Ren Tang Second Traditional Chinese Medicine Hospital and Nansanhuan Zhonglu Drugstore, achieved combined sales revenue of RMB 252,055,000, representing a year-on-year increase of 16.75%, and net profit of RMB 12,780,000, representing a year-on-year increase of 14.51%[46]. - Six subsidiaries engaged in the production of Chinese medicinal materials achieved sales revenue of RMB 424,488,000, representing a year-on-year increase of 58.80%[47]. Research and Development - Research and development expenses for the year were RMB 185,469,000, accounting for 2.74% of revenue, an increase from 2.24% in 2022[60]. - The Group focused on the secondary research of existing products and collaborated with experts for clinical research on major varieties[37]. - The Group's strategy for "Major Varieties" aims to ensure sufficient supply and enhance operational capacity to meet market demands[32]. Compliance and Risk Management - The Group has a strict quality management system in place to mitigate operational risks associated with the production of Chinese patent medicines[126]. - The Group's operations are subject to various laws and regulations, including the Company Law and the Law on Traditional Chinese Medicine, ensuring compliance through internal controls and training[133]. - The Group faces operational risks due to the complexity of production processes and potential supply chain disruptions from climate change and extreme weather[131]. - The Group has not encountered any significant legal risk events during the reporting period, indicating effective compliance management[134]. - The Group emphasizes the importance of integrity and compliance culture to support high-quality development[134]. Shareholder Information - The Group proposed a final dividend of RMB 0.18 per share for 2023, totaling RMB 230,541,000, up from RMB 204,925,440 in 2022[87]. - The company will withhold individual income tax at a rate of 20% for individual shareholders of H shares when distributing the final dividend[92]. - The company has not reached any arrangement for shareholders to waive any dividend as of the report date[93]. - As of December 31, 2023, the company's distributable reserves were approximately RMB 3,135,383,000, an increase from approximately RMB 2,877,188,000 in 2022[102]. - The company satisfied the public float requirement under rule 8.08 of the Listing Rules as of the report date[107]. Connected Transactions - The Group's continuing connected transactions with Tong Ren Tang Holdings include a Property Leasing Framework Agreement with an annual cap of RMB 60,000,000 for the three years ending December 31, 2025[143]. - In 2023, the rental fee paid by the Group to the Tong Ren Tang Group under the Property Leasing Framework amounted to RMB 846,000, which did not exceed the relevant annual cap[144]. - The Distribution Framework Agreement was renewed for three years from January 1, 2023, to December 31, 2025, with annual caps of RMB 2,680,000,000, RMB 3,000,000,000, and RMB 3,450,000,000 respectively[148]. - In 2023, sales to the Tong Ren Tang Group under the Distribution Framework Agreement amounted to RMB 1,590,404,000, which did not exceed the relevant annual cap[148]. - The Master Procurement Agreement was renewed for three years from January 1, 2023, to December 31, 2025, with annual caps of RMB 500,000,000, RMB 550,000,000, and RMB 600,000,000 respectively[151]. - In 2023, the purchase of relevant products from the Tong Ren Tang Group under the Master Procurement Agreement amounted to RMB 187,476,000, which did not exceed the relevant annual cap[151]. Environmental and Social Responsibility - The Group is committed to environmental protection, adhering to relevant laws such as the Environmental Protection Law of the People's Republic of China[139]. - Cash donations made by the Group during the reporting period were RMB 214,000, up from RMB 86,000 in 2022[104]. - The company made cash donations of RMB 21,400 during the reporting period, compared to RMB 8,600 in 2022, reflecting an increase of approximately 148.8%[109].

Financial Performance - The group's revenue for the year ended December 31, 2023, was RMB 6,773.5 million, an increase of 13.04% compared to RMB 5,991.8 million in the previous year[6]. - Net profit for the year was RMB 992.3 million, a decrease of 0.93% from RMB 1,001.6 million in the previous year[11]. - Profit attributable to owners of the company was RMB 590.2 million, up 1.25% from RMB 582.9 million in the previous year[11]. - Earnings per share remained stable at RMB 0.46, unchanged from the previous year[6]. - The total comprehensive income for the year was RMB 1,041.7 million, compared to RMB 1,264.8 million in the previous year[13]. - The profit before tax for 2023 was RMB 1,162,455,000, a decrease of 4.1% from RMB 1,211,993,000 in 2022[44]. - The total income tax expense for the year was RMB 170,142,000, down from RMB 210,373,000 in 2022, representing a decrease of approximately 19.1%[41]. - Basic earnings per share for 2023 remained stable at RMB 0.46, unchanged from 2022, with net profit attributable to owners of the company at RMB 590,188,000[49][50]. Assets and Liabilities - Total assets increased to RMB 13,507,742 thousand in 2023, up from RMB 12,484,768 thousand in 2022, representing a growth of approximately 8.2%[14]. - Total liabilities increased to RMB 3,855,857 thousand in 2023, up from RMB 3,467,830 thousand in 2022, reflecting an increase of around 11.2%[16]. - Total equity increased to RMB 9,651,885 thousand in 2023, up from RMB 9,016,938 thousand in 2022, representing a growth of approximately 7.0%[16]. - The company's total liabilities to equity ratio improved to 0.40 in 2023 from 0.38 in 2022, indicating a stronger equity position relative to liabilities[16]. - Cash and cash equivalents decreased to RMB 2,746,458 thousand in 2023 from RMB 3,721,668 thousand in 2022, a decline of about 26.2%[14]. - Accounts receivable decreased to RMB 888,333 thousand in 2023 from RMB 1,497,249 thousand in 2022, a decline of approximately 40.7%[14]. - Total accounts payable and notes increased to RMB 1,376,743,000 in 2023 from RMB 823,233,000 in 2022, indicating a significant rise in liabilities[67]. Revenue Segments - Revenue from traditional Chinese medicine products in mainland China reached RMB 5,495,458,000 in 2023, up from RMB 4,848,999,000 in 2022, representing an increase of approximately 13.3%[31]. - Total revenue for advertising services was RMB 6,708,635,000 in 2023, compared to RMB 5,929,362,000 in 2022, marking an increase of about 13.1%[31]. - The company’s total income from external customers in 2023 was RMB 5,991,841,000, reflecting growth in various segments[55]. - The company reported a significant increase in external customer revenue from the Tongrentang Traditional Chinese Medicine segment, reaching RMB 1,379,604,000 in 2023[53]. Expenses and Investments - Research and development expenses rose to RMB 117,556,000 in 2023, compared to RMB 78,433,000 in 2022, indicating an increase of about 49.9%[38]. - The group's sales expenses amounted to RMB 1,080.544 million, with a sales expense ratio of 0.16, up from 0.15 in 2022, primarily due to rising labor costs and increased promotional activities[86]. - Capital expenditures for the year ended December 31, 2023, were RMB 108 million, down from RMB 173 million in 2022, primarily for production facility construction and equipment purchases[89]. Strategic Initiatives - The company plans to leverage its century-old brand to enhance marketing and operational efficiency, aiming for high-quality development in 2024[9]. - The group will focus on core competitive advantages and innovative operations to meet market demands and complete its "14th Five-Year Plan" objectives[9]. - The company plans to enhance product management, channel expansion, and marketing capabilities in 2024, focusing on core product development and differentiated marketing strategies[95]. - The company is focusing on secondary research for existing products and is collaborating with experts and hospitals for clinical studies on major products[78]. - The company has implemented a "Big Variety" strategy to enhance product value and expand market coverage through various promotional activities[78]. Market Outlook - The Chinese traditional medicine industry is expected to continue its stable growth, supported by government policies and increasing health awareness among the public[7]. - The group anticipates continued growth in the traditional Chinese medicine industry in 2024, driven by government investment and increasing consumer health spending[94]. Governance and Compliance - The Audit Committee held three meetings in 2023 to review financial performance and compliance, ensuring the integrity of financial data and risk management systems[101]. - The company has adhered to the Corporate Governance Code and has implemented a robust governance framework[100]. - The company’s auditor, PwC, confirmed that the financial figures for the year ending December 31, 2023, are consistent with the draft consolidated financial statements[102].

Financial Performance - For the six months ended June 30, 2023, the group's sales revenue increased by approximately 30.91% compared to the same period in 2022, reaching RMB 3,946,415 thousand[5]. - The profit attributable to the owners of the company for the same period rose by approximately 15.65%, amounting to RMB 368,151 thousand[9]. - The earnings per share attributable to the owners of the company for the six months ended June 30, 2023, was RMB 0.29, compared to RMB 0.25 for the same period in 2022[9]. - The operating profit for the six months ended June 30, 2023, was RMB 640,630 thousand, an increase from RMB 560,131 thousand in the previous year[9]. - The total comprehensive income for the period was RMB 664,847 thousand, compared to RMB 578,553 thousand in the same period last year[11]. - The company reported a net profit attributable to owners of RMB 368,151,000 for the six months ended June 30, 2023, up from RMB 318,322,000 in the same period of 2022, representing a growth of 15.7%[43]. - Basic earnings per share for the six months ended June 30, 2023, was RMB 0.29, compared to RMB 0.25 for the same period in 2022, marking an increase of 16%[44]. - The company reported a profit of RMB 452,209,000 for the period, with a significant profit from the main segment of RMB 275,037,000[62]. Assets and Liabilities - As of June 30, 2023, total assets amounted to RMB 13,080,233 thousand, an increase from RMB 12,484,768 thousand as of December 31, 2022[14]. - The total liabilities as of June 30, 2023, were RMB 3,772,892 thousand, compared to RMB 3,467,830 thousand at the end of 2022[14]. - The total cash received from financing activities was 200,000 thousand RMB, while cash paid for financing activities was 208,695 thousand RMB, resulting in a net cash outflow from financing activities[16]. - The total assets of the company were reported at RMB 12,484,768,000, with total liabilities at RMB 3,467,830,000[64]. - The group reported an increase in accounts payable to RMB 909,419,000 as of June 30, 2023, compared to RMB 823,233,000 as of December 31, 2022[50]. - The net value of accounts receivable and notes was RMB 1,404,740,000 as of June 30, 2023, down from RMB 1,497,249,000 as of December 31, 2022[46]. Cash Flow - Operating cash flow for the period was 848,473 thousand RMB, compared to 531,447 thousand RMB in the previous period, representing a 59.8% increase[16]. - Net cash flow from investing activities was -376,022 thousand RMB, a significant improvement from -1,056,386 thousand RMB in the prior period[16]. - The company reported a net increase in cash and cash equivalents of 263,756 thousand RMB, contrasting with a decrease of 672,715 thousand RMB in the previous period[16]. - The company's cash and cash equivalents as of June 30, 2023, were RMB 4,064,607 thousand, up from RMB 3,721,668 thousand at the end of 2022[14]. - The initial cash balance at the beginning of the period was 3,721,668 thousand RMB, reflecting a solid liquidity position[16]. - The impact of foreign exchange rate changes on cash and cash equivalents was 79,183 thousand RMB, highlighting the influence of currency fluctuations on financial results[16]. Dividends and Shareholder Information - The company decided not to declare an interim dividend for the six months ended June 30, 2023[5]. - The company did not declare an interim dividend for the six months ended June 30, 2023, consistent with the previous year[43]. - As of June 30, 2023, there were no known interests or short positions held by directors, supervisors, or senior management in the company's shares[114]. - The company holds 600,000,000 shares, representing 92.01% of the domestic shareholding percentage[117]. - The total number of shares held by the company and its subsidiaries is 617,129,000, accounting for 93.46% of the domestic shareholding percentage[117]. Market and Product Development - The company is focused on expanding its market presence and enhancing its product offerings, as indicated by ongoing investments in new technologies and product development[25]. - The company has implemented a "big variety" strategy to enhance its core competitive advantages in brand, variety, and quality[81]. - The company has established a three-year sales framework agreement with its ultimate holding company, effective from January 1, 2023, to December 31, 2025[76]. - The company has also renewed a three-year procurement framework agreement with its ultimate holding company, ensuring procurement terms are not less favorable than those with independent third parties[76]. - The company is focusing on the research and development of existing products, including the clinical safety and effectiveness studies of major products[85]. - The company has expanded its retail presence in Hong Kong, opening a new retail outlet in Tseung Kwan O Plaza[85]. - The company continues to enhance its online and offline sales channels, leveraging e-commerce platforms for promotional activities[83]. Risk Management and Governance - The board of directors is responsible for evaluating acceptable risk levels and ensuring effective risk management and internal control systems are in place[108]. - The company has adopted a code of conduct for securities transactions by directors and supervisors, ensuring compliance with the standards set by the listing rules[105]. - The audit committee has reviewed the unaudited financial statements for the six months ending June 30, 2023, and found no issues with the accounting treatment[113]. - The company has a dedicated internal audit function to regularly review operations and identify risks, with reports submitted to the audit committee[108]. - The company continues to deepen risk management and internal control self-assessment efforts, proposing improvements to minimize operational risks[108]. Research and Development - Research and development expenses reached RMB 4,779.4 million, representing 1.21% of revenue, up from 0.89% in the previous year[98]. - The company focuses on developing four main product types: granules, water honey pills, tablets, and soft capsules[123]. - The company has a commitment from Tongrentang and the group company not to produce any competing products with the same name or type[120]. - The company has the right of first refusal for any new products developed by Tongrentang and the group company that fall within its main product categories[123]. - The independent non-executive directors will review compliance with the commitments at least once a year[123].